Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa

The 6-month efficacy and tolerance of an efavirenz-containing highly active antiretroviral therapy regimen in a large cohort of HIV-1-infected adults is presented. Considering the very high hepatic and cutaneous tolerance, efavirenz could be considered as a valuable first-line drug for women of childbearing age who agree to use contraception in sub-Saharan Africa, provided that the risk of teratogenicity should be closely monitored.